Reduced-Intensity Stem Cell Transplant for Non-Malignant Disorders
(HSCT+RIC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is reduced-intensity stem cell transplant using Alemtuzumab and Fludarabine generally safe for humans?
Alemtuzumab, used in stem cell transplants, can cause delayed immune recovery and increase the risk of viral infections. There are reports of serious side effects like acute kidney failure and blood clotting issues when used with Fludarabine, although these are rare. Safety varies, and careful monitoring is essential.12345
What makes the Reduced-Intensity Stem Cell Transplant treatment for non-malignant disorders unique?
This treatment is unique because it combines multiple drugs, including Alemtuzumab, Fludarabine, Hydroxyurea, Melphalan, and Thiotepa, to create a reduced-intensity regimen that may be less harsh on the body compared to traditional high-dose chemotherapy. This approach is particularly novel for non-malignant disorders, where standard treatments may not be well-established.678910
What data supports the effectiveness of the drug Alemtuzumab in the clinical trial for Reduced-Intensity Stem Cell Transplant for Non-Malignant Disorders?
Who Is on the Research Team?
Paul Szabolcs, MD
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
This trial is for patients with non-cancerous disorders like juvenile arthritis, bone marrow failure, primary immunodeficiency, anemia, and metabolic diseases. Participants must have proper organ function, no active malignancy or severe aplastic anemia, not be pregnant or nursing mothers, and should not have had a stem cell transplant in the last 6 months.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Reduced Intensity Conditioning (RIC)
Participants undergo reduced-intensity conditioning with Alemtuzumab, Hydroxyurea, Fludarabine, Melphalan, and Thiotepa prior to allogenic HSCT
Transplantation
Participants receive umbilical cord blood, bone marrow, or peripheral blood stem cell transplantation
Follow-up
Participants are monitored for safety, effectiveness, and late effects after transplantation
What Are the Treatments Tested in This Trial?
Interventions
- Alemtuzumab
- Fludarabine
- Hydroxyurea
- Melphalan
- Thiotepa
Alemtuzumab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Paul Szabolcs
Lead Sponsor